<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene therapy and other investigational approaches for hemophilia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene therapy and other investigational approaches for hemophilia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene therapy and other investigational approaches for hemophilia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Keith Hoots, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Magdalena Lewandowska, MD, CACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Shapiro, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3441008381"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemophilia A (factor VIII [factor 8] deficiency) and hemophilia B (factor IX [factor 9] deficiency) are X-linked hereditary coagulation factor deficiencies that result in lifelong bleeding disorders. However, optimal management is complex, and available therapies carry a number of costs and burdens.</p><p>Hemophilia A and B are attractive candidates for gene therapy. They are both monogenic disorders that can be adequately treated by raising factor levels. The deficient factor can be produced and delivered to the circulation by various cell types. Unlike immunodeficiency syndromes, hematopoietic stem cell transplant is not required. (See  <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Inherited single gene disorders'</a>.)</p><p>This topic discusses gene therapy for hemophilia and other investigational approaches under development. </p><p>Separate topic reviews discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Function of factors VIII and IX – (See  <a class="medical medical_review" href="/z/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemophilia diagnosis – (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic therapy and minor bleeding – (See  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of bleeding and surgery – (See  <a class="medical medical_review" href="/z/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B"</a>.)</p><p></p><p class="headingAnchor" id="H1080793224"><span class="h1">OVERVIEW OF STRATEGIES TO REDUCE BLEEDING RISK</span><span class="headingEndMark"> — </span>There are two main strategies to reduce bleeding risk, each of which has several potential approaches in development that are discussed in the following sections  (<a class="graphic graphic_figure graphicRef140259" href="/z/d/graphic/140259.html" rel="external">figure 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhancing factor activity</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gene therapy to replace the deficient factor – (See <a class="local">'Gene therapy'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Cellular therapy to transplant transduced cells capable of producing the deficient factor – (See <a class="local">'Cellular therapy'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Modifications to factor proteins such as half-life extension or subcutaneous administration – (See <a class="local">'Improvements to factor products'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Substitutes for the deficient factor such as bispecific monoclonal antibodies – (See <a class="local">'Substitutes for clotting factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreasing natural anticoagulants</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antisense therapeutics to reduce levels of targeted anticoagulants – (See <a class="local">'Fitusiran (AT antisense)'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Function-blocking monoclonal antibodies or small molecules – (See <a class="local">'Anti-TFPI'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Engineered versions of natural inhibitors – (See <a class="local">'Blocking activated protein C'</a> below.) </p><p></p><p class="headingAnchor" id="H1365401958"><span class="h1">GENE THERAPY</span><span class="headingEndMark"> — </span>Gene therapy is appealing because infusion of the gene therapy construct (or treated cells) can provide the deficient factor. Efforts to establish gene therapy approaches for hemophilia are underway in various countries around the world [<a href="#rid1">1</a>]. A small number of gene therapy constructs have been approved by the US Food and Drug Administration (FDA).</p><p>However, as stated in a 2021 review, aspects of this approach remain to be optimized and studied for longer durations, and clinician familiarity with the principles and logistics of gene therapy remains to be systematically addressed [<a href="#rid2">2</a>]. (See <a class="local">'General gene therapy principles'</a> below.)</p><p>Gene editing, which uses enzymes to alter the individual's native deoxyribonucleic acid (DNA) sequence rather than introducing a new copy of the gene, is under study for possible use in hemophilia [<a href="#rid3">3-5</a>]. (See  <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Gene editing'</a>.)</p><p class="headingAnchor" id="H3707351218"><span class="h2">General gene therapy principles</span><span class="headingEndMark"> — </span>Gene therapy is both easy to understand and remarkably complex. A guide is available with figures and a glossary to help clinicians discuss gene therapy with their patients [<a href="#rid6">6</a>]. </p><p>General information is provided by professional organizations such as:</p><p class="bulletIndent1"><span class="glyph">●</span>World Federation of Hemophilia (WFH; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwfh.org%2F&amp;token=Ppe7MR2Y7mkWqvWU%2FvbBSlIiYNbYiY61GL2o3IUkMyU%3D&amp;TOPIC_ID=134290" target="_blank">https://wfh.org/</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Hemophilia Foundation (NHF; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hemophilia.org%2Fbleeding-disorders-a-z%2Ftreatment%2Ffuture-therapies%2Ffrequently-asked-questions&amp;token=kvUHK4ABKqi1%2BQoSYEFUtXfEaMQioFNuiyesdEQ%2BA5ZqCGBqbF4XoNCcYp7TFhGjNlVWAyWe4PHYU%2Fcm7MTyXibZyTMv1NEMnVhywS0YhmS1ZBhEqXwk0BFkQs3%2F0%2BeH&amp;TOPIC_ID=134290" target="_blank">https://www.hemophilia.org/bleeding-disorders-a-z/treatment/future-therapies/frequently-asked-questions</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>International Society on Thrombosis and Haemostasis (ISTH; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgenetherapy.isth.org%2F&amp;token=uolbzQjaaP4BJFWRsIkgO%2Bqg6968Ew%2BgdPXpuoFxHxqz3n%2BmIkgb%2BAqkVfSyICRt&amp;TOPIC_ID=134290" target="_blank">https://genetherapy.isth.org/</a>)</p><p></p><p class="headingAnchor" id="H241604869"><span class="h3">Access to clinical trials</span><span class="headingEndMark"> — </span>Information and resources for enrolling in hemophilia gene therapy trials may be accessed by consulting: </p><p class="bulletIndent1"><span class="glyph">●</span>Websites including clinicaltrials.gov (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3DHemophilia%26term%3Dgene%2Btherapy&amp;token=gahCe%2BZBjq6dTEfw3x8ERhKaiT6YvbLrtn3I2Decmyo90l6pIKx3xb1EiX61PyruHk3nNrHf%2FAam5RDcwZT%2Bjv0orI284%2FlBYyBOFim%2FjK4%3D&amp;TOPIC_ID=134290" target="_blank">https://clinicaltrials.gov/ct2/results?cond=Hemophilia&amp;term=gene+therapy</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A local Hemophilia Treatment Center or Centre of Excellence</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>United States – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdbdgateway.cdc.gov%2FHTCDirSearch.aspx&amp;token=1mlbwnMpT7N3%2F4R%2FWqdzPELkvXjFiKf%2FyIrok0FunpJwg9nlFe88ih%2F6PkDiz4qjmRYjW010hAgjRmYRRL4zFA%3D%3D&amp;TOPIC_ID=134290" target="_blank">https://clinicaltrials.gov/ct2/results?cond=Hemophilia&amp;term=gene+therapy</a></p><p class="bulletIndent2"><span class="glyph">•</span>United Kingdom – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ukhcdo.org%2Fhome-2%2Fhaemophilia-centre-list%2Fhaemophiliacentresa-c%2F&amp;token=Yrx3yi7b83pql7MZushMApx5bsX%2FhKHclx66Yzn%2FYyRifkuH0yYqgAtG7X3a3OkbHmcQz%2F6lj%2FVptyrhVUW4kv5AoPck2q%2BaU%2B7M05s%2B6Xk%3D&amp;TOPIC_ID=134290" target="_blank">https://www.ukhcdo.org/home-2/haemophilia-centre-list/haemophiliacentresa-c/</a></p><p></p><p class="headingAnchor" id="H732197808"><span class="h3">Methodology</span><span class="headingEndMark"> — </span>Gene therapy introduces exogenous DNA into cells that can be used to produce a deficient protein. In monogenic disorders such as hemophilia, this may involve a wild-type factor gene or a modified gene with enhanced properties such as greater activity or longer half-life. (See  <a class="medical medical_review" href="/z/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX", section on 'Naturally-occurring gain-of-function variants'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target cell</strong> – Because the factor circulates in the bloodstream, the DNA can be transduced into cells with access to the circulation. Hepatocytes are considered an appropriate target cell for transduction because the liver is the site of synthesis of most clotting factors, including endogenous factor IX. Endogenous factor VIII is produced by hepatic endothelial cells. In gene therapy approaches, constructs for both <em>F8</em> and <em>F9</em> are transduced into hepatocytes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target factor level</strong> – Hemophilia is amenable to gene therapy because factor levels do not need to be raised to the normal range. Production of even a small amount of the missing factor (to raise the factor level from a baseline of 0 percent up to a level of 5 percent) is sufficient to convert the disease from one of frequent potentially life-threatening bleeding into a mild phenotype that no longer requires routine factor prophylaxis. Raising the factor level above 30 to 40 percent may be equivalent to curing the disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vector</strong> – A variety of technologies may be used to introduce the <em>F8 </em>or <em>F9</em> gene, either using ex vivo genetic modification followed by implantation of the modified cells, or direct injection of a vector carrying a construct that includes the normal gene into the patient [<a href="#rid7">7-11</a>]. Vectors that produce other coagulation factors such as factor VIIa, a protein to which individuals with hemophilia A or B have immunologic tolerance, may also be used [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1">Adeno-associated viruses (AAV) have become widely used vectors for gene therapy because they generally do not integrate into the nuclear genome and typically are replication-deficient, reducing the risk of insertional mutagenesis. The risk of any insertional mutagenesis awaits further human studies. Another issue with AAV vectors is that some individuals have natural immunity to specific serotypes of adenoviruses and AAV due to natural infection; preexisting neutralizing antibodies to these vectors can reduce efficacy of gene therapy, as demonstrated in some trials. (See  <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Types of vectors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eligibility</strong> – Preliminary gene therapy trials have included males with severe factor deficiency (factor activity &lt;1 to 2 percent). Other individuals with bleeding phenotypes may be included in the future.</p><p></p><p class="bulletIndent1">Individuals who have developed an inhibitor to factor have been excluded from gene therapy trials due to concerns about reduced efficacy. Eligibility may eventually be expanded to include these individuals. (See  <a class="medical medical_review" href="/z/d/html/1308.html" rel="external">"Inhibitors in hemophilia: Mechanisms, prevalence, diagnosis, and eradication"</a>.)</p><p></p><p class="bulletIndent1">Some individuals with severe liver disease or active viral hepatitis have been excluded from clinical trials due to concerns about hepatotoxicity. (See <a class="local">'Potential concerns'</a> below.)</p><p></p><p class="bulletIndent1">Children have been excluded from trials due to concerns about informed consent and the likelihood that normal liver growth with proliferation of liver cells would dilute an episomal vector, reducing efficacy over time. There is also a prevailing caution about gene modification in younger children until overwhelming evidence of safety has been demonstrated in adults, adolescents, and older children. (See <a class="local">'Potential concerns'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Gene therapy constructs are typically administered intravenously and home to the target cells (often hepatocytes) to which the vector has tropism. The dose is typically expressed as number of vector genomes per kg of patient weight (vg/kg) [<a href="#rid2">2</a>]. This can be done as an outpatient procedure with close follow-up for development of adverse effects, including short-term infusion-related reactions and longer-term transaminase elevations. Efficacy measures including factor levels and bleeding events are monitored longitudinally. (See <a class="local">'Clinical experience with gene therapy'</a> below.)</p><p></p><p>Regardless of the methods used, the goal of gene therapy may not be restoration of a normal factor level, as conversion from a severe to a mild phenotype would result in significant improvement. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H1901334536"><span class="h3">Potential concerns</span><span class="headingEndMark"> — </span>Several concerns have been raised based on reduced efficacy and/or adverse effects observed in clinical trials or in preclinical models [<a href="#rid2">2,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eligibility</strong> – Some individuals may not be eligible for gene therapy due to preexisting immunity to the vector, preexisting antibodies (inhibitors) to the factor, or underlying liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of effect</strong> – The longest period of follow-up for any hemophilia gene therapy construct is &lt;10 years, with the longest available follow-up data for factor IX deficiency. Thus, the durability of response has not been definitively established for any gene therapy product. Declining factor VIII levels over time have been observed; durability of expression is under study. (See <a class="local">'Hemophilia A'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – If episomal therapies are used in children, ongoing proliferation of liver cells may dilute the number of viral genomes, possibly reducing factor levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variable expression</strong> – Interindividual expression variability remains unexplained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term complications</strong> – Several years of data on toxicity are reassuring, yet longer-term data remain to be collected. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatotoxicity</strong> – Several studies have demonstrated increased transaminases or decreased factor levels; glucocorticoids have been used to reduce the presumed viral vector inflammatory response that can lead to vector loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Integration and oncogenesis</strong> – Certain vectors (such as those based on retroviruses) carry a theoretical risk of insertional mutagenesis that may cause malignancy. The risk of late genotoxicity with AAV-based therapies is felt to be reduced because these vectors do not integrate as readily into the nuclear genome [<a href="#rid15">15</a>]. However, even non-integrating vectors such as AAV can integrate into the nuclear genome in small amounts. The clinical significance and risk of malignancy in the long-term is unknown [<a href="#rid16">16,17</a>]. Nonetheless, because the number of vector particles used to insert the transgene into the target cell for transcription (as high as 0.6 x 10<sup>6</sup> in one therapeutic strategy), even a very low rate of insertion could result in many target cells with insertional events [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1">One individual who received the hemophilia B gene therapy construct <a class="drug drug_general" data-topicid="140253" href="/z/d/drug information/140253.html" rel="external">etranacogene dezaparvovec</a> developed hepatocellular carcinoma; a subsequent detailed investigation concluded that the predisposing factor was not the gene therapy vector, based on no demonstration of proximal insertion of the AAV machinery near a known enhancer or promoter of clonality [<a href="#rid18">18-20</a>]. (See <a class="local">'Hemophilia B'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunity to the vector</strong> – Certain vectors may elicit a host immune response to viral proteins made by the vector, which could potentially complicate repeat dosing. Possible approaches to facilitating re-transduction in this setting are under investigation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission to other individuals</strong> – Patients should be counseled to consider using male barrier contraception for a minimum of six months after receiving AAV-mediated gene therapy treatment and to avoid donating blood, organs, tissues, or cells after receiving AAV-mediated gene therapy [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1">Gene therapy vectors are shed for a period of time, potentially exposing other individuals. Preclinical studies and early experience suggest that vector shedding can occur transiently in semen [<a href="#rid22">22-25</a>]. </p><p></p><p class="bulletIndent1">Patients who have received a gene therapy construct are counseled to abstain from sexual intercourse until it has been demonstrated that vector shedding is no longer occurring. In gene therapy clinical trials, participants were required to use barrier contraceptive measures to eliminate the risk of reproductive transmission until clearance of vector shedding [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vector DNA clearance was assessed using a qPCR assay, which does not measure infectious risk [<a href="#rid26">26,27</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Participants with three consecutive semen samples below the accepted limit of detection (LOD) &lt;400 copies/mL could discontinue use of barrier contraception [<a href="#rid5">5,6</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vector clearance from semen occurred between 12 and 78 weeks.</p><p></p><p class="headingAnchor" id="H1152258685"><span class="h2">Clinical experience with gene therapy</span><span class="headingEndMark"> — </span>Early gene therapy trials have focused on adults (males) with factor activity &lt;1 to 2 percent who have not developed inhibitors [<a href="#rid2">2,5</a>].</p><p class="headingAnchor" id="H3185467224"><span class="h3">Hemophilia A</span><span class="headingEndMark"> — </span>The <em>F8 </em>gene can be modified to remove the B-domain; this is the construct used in recombinant factor VIII replacement products. (See  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Recombinant human factor VIII'</a>.)</p><p>The B-domain deleted <em>F8</em> gene is smaller (<em>F8</em> is a very large gene that barely fits [or cannot fit] in the adeno-associated viruses [AAV] vectors). The following gene therapy constructs have been evaluated:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approved therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="141902" href="/z/d/drug information/141902.html" rel="external">Valoctocogene roxaparvovec</a> – The first gene therapy construct for hemophilia A to be approved in the European Union was valoctocogene roxaparvovec (approved as Roctavian) in 2022 [<a href="#rid28">28</a>]. This therapy was approved by the US FDA in June 2023 [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2">This construct uses a codon-optimized adeno-associated virus serotype 5 (AAV5) vector containing a gene for B-domain deleted human factor VIII (AAV5-hFVIII-SQ) [<a href="#rid30">30</a>]. The AAV5 vector (and the AAV virus on which it is based) is a non-integrating hepatotrophic vector that remains mostly episomal, although a very small amount integrates into the nuclear genome. (See  <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Integrating versus nonintegrating vectors'</a>.)</p><p></p><p class="bulletIndent2">The approval is for adults with severe hemophilia A without an inhibitor and with no antibodies to AAV5. The dose is 6 × 10<sup>13</sup> vector genomes per kilogram (vg/kg), administered as a single intravenous infusion. Other aspects of administration (monitoring of factor VIII and liver function, and indications for glucocorticoids) are described in the product label [<a href="#rid28">28</a>]. Factor VIII activity is expected to rapidly increase over the first six months and then to decline (at first rapidly and then more gradually) but to maintain effective levels, as described in the studies below.</p><p></p><p class="bulletIndent2">Efficacy and safety of this construct was reported in a 2022 study involving 134 males with severe hemophilia A (baseline factor VIII activity ≤1 percent) who were followed for ≥1 year after receiving the therapy at a dose of 6 x 10<sup>13</sup> vg per kg intravenously [<a href="#rid31">31</a>]. Individuals who were positive for anti-AAV5 capsid antibodies were not eligible to participate in the trial.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Efficacy</strong> – There were clinically meaningful improvements in bleeding rates due to sustained increases in factor VIII activity [<a href="#rid31">31</a>]. The mean annualized bleeding rate decreased from 4.8 with prior prophylaxis to 0.8 after the gene therapy, and the mean annualized number of factor VIII infusions decreased from 136 to 2. Factor VIII activity levels (assayed by chromogenic substrate) remained increased above baseline through the end of the year (mean, 43 units/dL). Factor VIII activity &gt;40 units/dL was seen in 50 participants (38 percent) and &lt;5 units/dL in 16 participants (12 percent). </p><p></p><p class="bulletIndent3">Durability of the therapy was evaluated in an extension study that followed these 134 individuals for two years and found continued efficacy during weeks 53 to 104 (annualized bleeding rate, 0.7, with declining factor VIII usage in the second and third years) [<a href="#rid32">32</a>]. The mean factor VIII activity at week 104 was 22 units/dL. Modeling of the half-life of the construct provided an estimated half-life of 123 weeks and extrapolated mean factor VIII activity of 12 units/dL at week 260 (year 5).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Safety</strong> – Adverse events in the initial and extension studies were common and mostly mild [<a href="#rid31">31,32</a>]. The most common was an increase in alanine aminotransferase (in 86 to 89 percent); these elevations were mostly treated with glucocorticoids (in &gt;80 percent); some were treated with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (18 percent) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> (10 percent). Serious adverse events related to the study drug were seen in 4 percent (mostly hypersensitivity reactions, including one anaphylaxis), all in the first year of therapy. Glucocorticoid-related adverse events were common. There were no deaths, thromboses, or inhibitor development. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapies under investigation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SPK-8011 </strong>– This construct uses an AAV-LK3 vector with a liver-specific promoter and a codon-optimized, B-domain deleted <em>F8 g</em>ene. In a series of 18 individuals with severe hemophilia A treated in various dose cohorts (from 5 x 10<sup>11 </sup>vg per kg to 2 x 10<sup>12 </sup>vg per kg) observed for a median of three years, 16 had preserved factor VIII expression [<a href="#rid23">23</a>]. Two individuals, both in the highest dose cohort, lost factor VIII expression due to an immune response to the AAV capsid, despite immunosuppression. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Efficacy</strong> – Peak factor levels occurred at 6 to 12 weeks after infusion. For the entire cohort, the annualized bleeding rate decreased from a median of 8.5 events per year before infusion to 0.3 events per year after infusion, a 92 percent reduction. Factor infusions decreased from a median of 58 per year to 0.6 per year. In 15 individuals who were followed for &gt;1 year, factor activity levels were stable at 11±7 percent. Factor activity levels remained stable in 12 individuals who were followed for &gt;2 years. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Safety </strong>– Therapy was well-tolerated, with an infusion reaction in one participant 12 hours after receiving the construct and transaminase elevations in seven. Four participants had adverse effects related to glucocorticoids used to reduce liver toxicity. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Giroctogcogene fitelparvovec</strong> – Giroctocogene fitelparvovec (formerly SB-525) has shown good efficacy in 5 individuals, based on unpublished data [<a href="#rid33">33</a>]. Additional studies are ongoing. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other constructs</strong> – Several other gene therapy constructs for hemophilia A are in various stages of development [<a href="#rid5">5,14</a>]. Some of these have used a retroviral vector or a non-viral, plasmid-based system [<a href="#rid22">22,34</a>]. These have been effective in raising factor VIII activity levels and have generally been well-tolerated, although vector shedding remains possible [<a href="#rid22">22</a>]. (See <a class="local">'Potential concerns'</a> above.)</p><p></p><p>A variant in the <em>F8</em> gene that increases expression levels was identified in 2021 and has not yet been incorporated into gene therapy constructs. (See  <a class="medical medical_review" href="/z/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX", section on 'Factor VIII Padua'</a>.)</p><p class="headingAnchor" id="H2295475360"><span class="h3">Hemophilia B</span><span class="headingEndMark"> — </span>The <em>F9</em> Padua variant (<em>F9</em> p.R338L) contains a naturally occurring missense mutation in the <em>F9</em> gene that increases its activity approximately 4 to 40-fold; this construct has been used in most of the factor IX gene therapy trials. It is appealing because it provides enhanced factor IX activity. Individuals are generally excluded from clinical trials if they have factor IX inhibitors or neutralizing antibodies against the viral vector used to deliver the gene therapy construct. (See  <a class="medical medical_review" href="/z/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX", section on 'Factor IX Padua'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>FDA-approved</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="140253" href="/z/d/drug information/140253.html" rel="external">Etranacogene dezaparvovec</a> – Etranacogene dezaparvovec (formerly AMT-061) is an AAV5 vector containing <em>F9</em> Padua with a liver-specific promoter. It was approved by the FDA in November 2022 (as Hemgenix) for adults with hemophilia B using factor IX prophylaxis or those with a history of life-threatening bleeding or repeated serious bleeding [<a href="#rid35">35</a>]. It is given as a single intravenous dose.</p><p></p><p class="bulletIndent2"><strong>Supporting evidence:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Efficacy</strong> – An initial study at a dose of 2 x 10<sup>13</sup> vg/kg in three males with severe hemophilia B demonstrated reduced bleeding (no bleeds during the study period) and increased factor IX activity levels (mean factor IX activity of 31 percent at six weeks and 47 percent at 26 weeks) [<a href="#rid36">36</a>]. A previous study with an earlier construct (codon-optimized factor IX in the same AAV5 vector) in 10 men with hemophilia B was similarly effective [<a href="#rid37">37</a>]. The HOPE-B study, which followed 53 participants for 18 months, reported reduction in annualized bleeding rate (ABR) from 4.19 to 1.51, with reduced use of <a class="drug drug_general" data-topicid="88578" href="/z/d/drug information/88578.html" rel="external">factor IX concentrate</a> by a mean of 248,825 units per year per participant in the post-treatment period [<a href="#rid38">38</a>]. One patient discontinued treatment after a hypersensitivity reaction with the initial drug infusion; he received approximately 10 percent of the full dose and did not have a response to treatment.</p><p></p><p class="bulletIndent3">Transduction was effective even in individuals with preexisting immunity to the AAV vector up to a titer of 678 (in 21 of 54 patients). Treatment did not produce a response in one patient with an AAV5 neutralizing antibody titer of 3212.</p><p></p><p class="bulletIndent3">Factor IX activity measured with the chromogenic assay was lower than when measured with the activated partial thromboplastin time (aPTT)-based assay, reported at 16.5±8.8 versus 39±18.7 percent at six months. Expression appears to be stable at three years after treatment [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Safety </strong>– Elevations in alanine transaminase (ALT) were seen in 11 of 54 (20 percent); most elevations were mild to moderate. Glucocorticoids were used in 9 of the 11, with a mean duration of 80 days. Infusion-related adverse events were seen in 13 percent. One individual developed liver cancer; a detailed analysis concluded that the predisposing factor was not the gene therapy vector, as discussed above (see <a class="local">'Potential concerns'</a> above) [<a href="#rid18">18-20</a>]. One patient died of cardiogenic shock that was considered not to be treatment related. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Under investigation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Verbrinacogene setparvovec </strong>– Verbrinacogene setparvovec (formerly FLT180a) is a synthetic AAV vector (AAVS3, designed for increased liver transduction) containing F9 Padua. A dose-finding study in 10 males with hemophilia B and baseline factor IX activity &lt;2 percent reported a decrease in mean annualized bleeding rate from 2.93 per year (range, 0 to 7.33) to 0.71 per year (range, 0 to 1.7) [<a href="#rid40">40</a>]. Only one person resumed factor IX replacement therapy; the other nine had factor IX activity of 28 to 279 percent. Adverse effects were as expected including transaminase elevations and side effects of immunosuppressive therapies (<a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, with or without <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>). Thrombosis occurred in one individual with high factor IX activity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fidanacogene elaparvovec</strong> – Fidanacogene elaparvovec (formerly SPK-9001) is an AAV vector containing <em>F9</em> Padua. Results from a study in 10 males with hemophilia B and baseline factor IX activity &lt;2 percent who were treated with a single-stranded AAV construct with liver tropism and liver-specific regulatory elements (AAV SPK-9001) expressing <em>F9</em> Padua produced a mean steady state factor IX expression level of 33.7 percent (range, 14 to 81 percent), and a reduction in mean annualized bleeding rate from 11.1 to 0.4 events per year [<a href="#rid41">41,42</a>]. A low dose of vector (5 x 10<sup>11</sup> vg/kg) was administered as a means of minimizing host antiviral immunity. There were no serious adverse events and no evidence of inhibitor development. Two individuals who had transient increases in liver function tests were treated with a course of glucocorticoids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other constructs</strong> – Earlier studies showed efficacy of other constructs such as an AAV8 vector expressing a codon-optimized <em>F9</em> gene that produced dose-dependent increases in factor IX levels in 10 individuals (range, 1 to 6 percent, versus pre-study levels of &lt;1 percent) [<a href="#rid43">43,44</a>]. A follow-up study demonstrated that these increases persisted over a median of 3.2 years. Annualized bleeding rates decreased from 16 to 2, and four of seven patients were able to discontinue factor IX prophylaxis. Transient, asymptomatic elevations in alanine aminotransferase levels with corresponding reductions in factor IX activity and increased numbers of AAV8-reactive T lymphocytes were seen in four individuals, suggesting a loss of transduced hepatocytes. These reactions responded to administration of a short course of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>. There were no other major adverse events or factor IX inhibitors [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H3690238133"><span class="h1">CELLULAR THERAPY</span><span class="headingEndMark"> — </span>Cellular therapy involves introducing intact cells into the patient rather than manipulation of coagulation factor genes. Autologous cells may be treated with a gene therapy construct outside the body and then re-introduced. Foreign cells may be enclosed in immuno-protective devices before implantation to prevent rejection. </p><p class="bulletIndent1"><span class="glyph">●</span>A plasmid-based system was used to transfect autologous dermal fibroblasts with the gene for factor VIII and these cells were injected into the omentum [<a href="#rid34">34</a>]. Administration of autologous bone marrow cells transduced outside the body with a lentiviral vector is also under investigation. This strategy will likely require some degree of myeloablation before reintroduction of the ex-vivo modified hematopoietic cells into the individual. This may, in turn, raise concerns about clonal hematopoiesis, based on observations in individuals with sickle cell disease. (See  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Concern about myeloid malignancy in gene therapy studies'</a> and  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a mouse model of hemophilia A, transplantation of liver sinusoidal endothelial cells from non-hemophilic donor animals resulted in increased factor levels and correction of the bleeding phenotype [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/4593.html" rel="external">"Hepatocyte transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A polymer-encapsulated human cell system to express factor VIII (SIG-001) was under development but is no longer being pursued due to development of a factor VIII inhibitor in one recipient [<a href="#rid46">46-48</a>].</p><p></p><p class="headingAnchor" id="H3208813035"><span class="h1">IMPROVEMENTS TO FACTOR PRODUCTS</span></p><p class="headingAnchor" id="H4021102704"><span class="h2">Half-life extension</span><span class="headingEndMark"> — </span>Several modified factor products are available with extended half-life. The major benefit is an extended interval between doses, which reduces the risks and burdens of intravenous access. Examples include recombinant fusion to the immunoglobulin Fc region or albumin, or PEGylation. (See  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Longer lasting recombinant factor VIII'</a> and  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Longer-lasting recombinant factor IX'</a>.)</p><p>For factor VIII, a main determinant that limits half-life extension is the requirement of binding to von Willebrand factor (VWF) for stabilization. A recombinant factor VIII fusion to VWF (efanesoctocog alfa [Altuviiio]) circumvents this dependence, leading to a significant prolongation of half-life that allows once-weekly administration. (See  <a class="medical medical_review" href="/z/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX", section on 'Binding to von Willebrand factor'</a> and  <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'VWF functions'</a> and  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Efanesoctocog alfa (factor VIII-VWF fusion)'</a>.)</p><p class="headingAnchor" id="H2269729368"><span class="h2">Subcutaneous administration</span><span class="headingEndMark"> — </span>No subcutaneous factor products are clinically available (<a class="drug drug_general" data-topicid="115772" href="/z/d/drug information/115772.html" rel="external">emicizumab</a> is given subcutaneously but is not a factor product). Subcutaneous administration would potentially eliminate the need for intravenous access or central venous catheter placement for administration of routine prophylaxis. (See  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A'</a>.)</p><p class="headingAnchor" id="H1937400076"><span class="h1">SUBSTITUTES FOR CLOTTING FACTORS</span></p><p class="headingAnchor" id="H1113020529"><span class="h2">Bispecific humanized monoclonal antibodies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115772" href="/z/d/drug information/115772.html" rel="external">Emicizumab</a> is a bispecific humanized monoclonal antibody used for prophylaxis in hemophilia A. (See  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A'</a>.)</p><p>Mim8 is another bispecific antibody under development that also mimics the role of factor VIIIa in bringing together factor IXa and factor X, restoring tenase function. Like <a class="drug drug_general" data-topicid="115772" href="/z/d/drug information/115772.html" rel="external">emicizumab</a>, it can be administered subcutaneously in individuals with hemophilia A, both with and without inhibitors [<a href="#rid49">49</a>]. In hemophilia A plasma and whole blood, Mim8 normalized thrombin generation and clot formation, with potencies 13 and 18 times higher than a sequence-identical analog of emicizumab. </p><p class="headingAnchor" id="H3509546285"><span class="h1">REDUCING NATURAL ANTICOAGULANTS</span><span class="headingEndMark"> — </span>Some individuals with hemophilia who also carry a prothrombotic gene variant such as factor V Leiden (FVL) or antithrombin (AT) deficiency have been reported to have less frequent or milder bleeding. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p>These observations have led to the development of approaches that target endogenous anticoagulant proteins, in effect "rebalancing" the equilibrium between procoagulant and anticoagulant factors.</p><p>Since they increase thrombin generation generally rather than by correcting a specific factor deficiency, these therapies have the potential to reduce bleeding regardless of the deficient procoagulant.</p><p class="headingAnchor" id="H509798694"><span class="h2">Anti-TFPI</span><span class="headingEndMark"> — </span>Tissue factor pathway inhibitor (TFPI) is a natural inhibitor of coagulation that prevents unchecked amplification of the clotting cascade. It acts in two ways, both inhibiting factor Xa and preventing generation of factor Xa by the extrinsic pathway (tissue factor and factor VIIa). (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Control mechanisms and termination of clotting'</a> and  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Tissue factor pathway inhibitor'</a>.)</p><p>Factor VIII and IX deficiencies reduce thrombin generation via the intrinsic pathway. Monoclonal antibodies against TFPI have the potential to improve hemostasis by allowing generation of higher local concentrations of factor Xa and thrombin by the extrinsic and common pathways. One monoclonal antibody, befovacimab, was not pursued because three individuals in an early study developed thromboses (one venous and two arterial) in the central nervous system [<a href="#rid50">50</a>]. </p><p>An anti-TFPI RNA aptamer was not pursued due to high bleeding rates at the highest dose level [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H876821397"><span class="h3">Concizumab</span><span class="headingEndMark"> — </span>Concizumab (previously called mAb2021) is a monoclonal antibody against TFPI that can be administered subcutaneously (as done in clinical trials) or intravenously. It was approved in Canada in 2023 for adults and adolescents (≥12 years) with hemophilia B who have inhibitors and require routine prophylaxis [<a href="#rid52">52</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The dose is 1 mg/kg loading dose, followed by 0.2 mg/kg daily, followed by individualized dosing based on plasma concizumab level determined at week 4. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – Prescribing information contains a warning about the risk of thrombotic events. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence for efficacy</strong> – The following data are available regarding efficacy and safety:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2023 trial (Explorer7) enrolled 133 patients ages ≥12 years who had hemophilia A or B and inhibitors [<a href="#rid53">53</a>]. Of these, 52 patients were randomly assigned to receive concizumab or placebo, and 81 received concizumab without randomization. The trial started with a higher initial dose of concizumab and was put on hold after thromboembolic events occurred in three individuals; after the hold, the starting dose was reduced to 1 mg/kg, followed by 0.2 mg/kg daily (potentially adjusted at week 4 based on plasma concizumab concentration). Among randomized patients, the estimated mean annualized bleeding rate was 1.7 with concizumab versus 11.8 in controls (rate ratio 0.14, 95% CI 0.07-0.29). When the nonrandomized patients were included, the mean annualized bleeding rate with concizumab was 0. There were no additional thromboembolic events after the trial was restarted at the lower concizumab dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2019 trial involving 53 individuals (36 with hemophilia A, 9 with hemophilia A and inhibitors, and 8 with hemophilia B with inhibitors) treated with concizumab prophylaxis versus on-demand rFVIIa found a significant reduction in the annualized bleeding rate with concizumab; there was an 80 to 90 percent greater reduction in bleeding than seen with on-demand rFVIIa (annualized bleeding rate with concizumab, 4.5, versus 20.4 with rFVIIa) [<a href="#rid54">54</a>]. Concizumab was given subcutaneously once daily at a starting dose of 0.15 mg/kg and increased as needed based on a defined number of breakthrough bleeding events over a period of time. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Earlier studies in people with hemophilia A and B, healthy volunteers, and preclinical models demonstrated good hemostatic efficacy [<a href="#rid55">55-57</a>].</p><p></p><p class="headingAnchor" id="H3040233474"><span class="h3">Marstacimab</span><span class="headingEndMark"> — </span>Marstacimab (previously called PF-06741086) is a monoclonal antibody against TFPI that can be administered subcutaneously or intravenously [<a href="#rid50">50</a>]. Unpublished data in a series of 26 individuals with hemophilia A or B treated in various dose cohorts of marstacimab for six months suggest that the annualized bleeding rate was reduced by 80 to 96 percent across the marstacimab dose cohorts [<a href="#rid50">50</a>]. Thrombotic complications were not observed. </p><p class="headingAnchor" id="H996075941"><span class="h2">Reducing AT</span><span class="headingEndMark"> — </span>AT is a natural anticoagulant that inhibits thrombin (factor IIa), factor Xa, and other serine proteases in the coagulation cascade such as factor IXa. Reduced AT activity can lead to a prothrombotic state. (See  <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">"Antithrombin deficiency", section on 'Pathophysiology'</a> and  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Antithrombin, heparin, and heparan'</a>.)</p><p>While reducing AT could reduce bleeding risk, there is concern about prothrombotic risk, as seen with fitusiran. (See <a class="local">'Fitusiran (AT antisense)'</a> below.)</p><p class="headingAnchor" id="H3875168620"><span class="h3">Fitusiran (AT antisense)</span><span class="headingEndMark"> — </span>Fitusiran is an antisense oligonucleotide (ASO) against AT (encoded by the <em>SERPINC1</em> gene) that can be administered subcutaneously. </p><p>A 2023 trial that randomly assigned 57 males age ≥12 years with hemophilia A or B with inhibitors who were using bypassing agents as needed to receive fitusiran 80 mg subcutaneously or to continue using bypassing agents documented reduced bleeding with fitusiran [<a href="#rid58">58</a>]. The mean annualized bleeding rate in the fitusiran group was 1.7 (95% CI 1.0-2.7) compared with a mean annualized bleeding rate in the control group of 18.1 (95% CI 10.6-30.8). There were no bleeds in 25 of 38 participants (66 percent) in the fitusiran group versus 1 of 19 (5 percent) in the control group. Adverse events with fitusiran included increased alanine aminotransferase (ALT) in approximately one-third and thromboembolic events in two individuals (5 percent); there were no deaths. </p><p>In a previous study of 25 individuals treated with fitusiran that showed a reduction in annualized bleeding rate, a patient died following cerebral venous sinus thrombosis [<a href="#rid59">59-61</a>]. The study was temporarily halted and then restarted after investigation showed the patient had been diagnosed with a subarachnoid hemorrhage that was treated with clotting factor in excess of study guidelines. Phase 3 studies were again paused in October 2020 as a result of four additional nonfatal thrombotic events [<a href="#rid62">62</a>]. Thrombosis risk appeared to correlate with the degree of antithrombin (AT) reduction, with highest risk in participants with AT levels &lt;10 percent (5.91 per 100 patient years). The protocol was adjusted to target AT levels of 15 to 35 percent to mitigate thrombotic risk, and a follow-up publication in 2021 did not report thrombotic complications [<a href="#rid63">63</a>]. </p><p>However, the possibility exists that a prothrombotic stimulus such as severe injury or infection (such as coronavirus disease 2019 [COVID-19]) could further increase prothrombotic risk if AT concentrate is not administered.</p><p>Prior pharmacokinetic analysis showed that the drug had a short half-life in the plasma (three to five hours), but the reduction of AT levels persists for several weeks [<a href="#rid59">59</a>]. The monthly regimen used in the initial study induced a dose-dependent reduction of AT (mean maximum reduction, 70 to 89 percent from baseline). A reduction in the AT level of &gt;75 percent from baseline resulted in mean peak thrombin values at the lower end of the range seen in individuals without hemophilia. </p><p class="headingAnchor" id="H207221839"><span class="h2">Blocking activated protein C</span><span class="headingEndMark"> — </span>Activated protein C (aPC) is a natural inhibitor of coagulation that proteolyzes factors such as activated factor V (factor Va). </p><p>Factor V Leiden (FVL) is a variant of factor V (a point mutation) that is resistant to aPC. (See  <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">"Factor V Leiden and activated protein C resistance", section on 'Physiology'</a>.)</p><p class="headingAnchor" id="H2099823284"><span class="h3">Modified SERPINs</span><span class="headingEndMark"> — </span>Natural inhibitors of aPC exist, including protein C inhibitor (PCI) and alpha-1 antitrypsin (AAT); these are referred to as serine protease inhibitors (SERPINs). aPC also has roles in inflammatory signaling; there have been concerns that disruption of aPC function could have effects beyond the coagulation cascade. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency", section on 'AAT genetics'</a>.)</p><p>To circumvent the other roles of aPC, modified versions of natural SERPINs have been created that specifically block aPC activity in the coagulation cascade without disrupting other pathways, and these are under investigation as possible therapies for hemophilia.</p><p class="headingAnchor" id="H215174639"><span class="h3">Monoclonal antibody that blocks aPC</span><span class="headingEndMark"> — </span>SR604 is a monoclonal antibody directed against aPC that blocks the binding of aPC to factor Va and prevents the natural anticoagulant function of aPC but does not interfere with endothelial barrier and anti-inflammatory functions. In a mouse model of hemophilia, SR604 reduced bleeding and shortened clotting times without causing thrombosis [<a href="#rid64">64</a>]. </p><p class="headingAnchor" id="H268055635"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112393.html" rel="external">"Society guideline links: Hemophilia A and B"</a>.)</p><p class="headingAnchor" id="H2052186752"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83610.html" rel="external">"Patient education: Hemophilia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2554719044"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for new therapies</strong> – Despite numerous factor products and other prophylactic therapies, optimal management of hemophilia is complex, and available therapies carry a number of costs and burdens. Several types of investigational therapy are under development  (<a class="graphic graphic_figure graphicRef140259" href="/z/d/graphic/140259.html" rel="external">figure 1</a>), including gene therapy, cellular therapy, modified factor products, novel factor alternatives, and therapies to reduce natural anticoagulants. (See <a class="local">'Introduction'</a> above and <a class="local">'Overview of strategies to reduce bleeding risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increasing factor activity</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gene therapy</strong> – Gene therapy introduces exogenous DNA into cells to produce the missing factor. Hepatocytes are considered an ideal target cell for clotting factor genes. Some individuals may not be eligible for gene therapy due to preexisting immunity to the vector, preexisting antibodies (inhibitors) to the factor, underlying liver disease, or age (liver still growing in young children). Durability of factor expression after gene therapy appears to be more of a challenge for factor VIII than for factor IX; long-term follow-up is needed to assure safety and efficacy. Data for specific constructs are presented above. (See <a class="local">'Gene therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cellular therapy</strong> – Autologous cells treated outside the body with gene therapy or foreign cells can be used to produce the deficient factor. These approaches are in early stages of development. (See <a class="local">'Cellular therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Factor half-life extension</strong> – Various approaches to extending factor half-life are in development. Recombinant longer half-life products are already in use for hemophilia A and B. (See <a class="local">'Half-life extension'</a> above and  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Longer lasting recombinant factor VIII'</a> and  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Longer-lasting recombinant factor IX'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Factor alternatives</strong> – Bifunctional monoclonal antibodies (mAbs) that replace the function of the deficient factor are in development. <a class="drug drug_general" data-topicid="115772" href="/z/d/drug information/115772.html" rel="external">Emicizumab</a> is one such product that is already approved and in wide use for hemophilia A. (See <a class="local">'Substitutes for clotting factors'</a> above and  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing natural anticoagulants</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anti-TFPI</strong> – mAbs against tissue factor pathway inhibitor (TFPI) such as concizumab and marstacimab allow generation of higher local concentrations of factor Xa and thrombin by the extrinsic and common pathways. (See <a class="local">'Anti-TFPI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reducing antithrombin</strong> – Fitusiran is an antisense oligonucleotide (ASO) against antithrombin (AT, encoded by <em>SERPINC1</em>) that prevents proteolysis of thrombin, factor Xa, and other serine proteases. Concerns about increased thrombotic risk have been raised and a revised dosing strategy has been implemented. (See <a class="local">'Fitusiran (AT antisense)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blocking aPC</strong> – Modified versions of natural serine protease inhibitors (SERPINs) that specifically block activated protein C (aPC) without disrupting other pathways are under investigation. A monoclonal antibody directed against aPC is also being studied. (See <a class="local">'Blocking activated protein C'</a> above.)</p><p></p><p class="headingAnchor" id="H470863555"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lawrence LK Leung, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reiss UM, Mahlangu J, Ohmori T, et al. Haemophilia gene therapy-Update on new country initiatives. Haemophilia 2022; 28 Suppl 4:61.</a></li><li><a class="nounderline abstract_t">Pipe SW. Delivering on the promise of gene therapy for haemophilia. Haemophilia 2021; 27 Suppl 3:114.</a></li><li><a class="nounderline abstract_t">Morishige S, Mizuno S, Ozawa H, et al. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs. Int J Hematol 2020; 111:225.</a></li><li><a class="nounderline abstract_t">Pipe SW, Selvaraj SR. Gene editing in hemophilia: a "CRISPR" choice? Blood 2019; 133:2733.</a></li><li><a class="nounderline abstract_t">Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood 2019; 133:407.</a></li><li><a class="nounderline abstract_t">Sidonio RF Jr, Pipe SW, Callaghan MU, et al. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev 2021; 47:100759.</a></li><li><a class="nounderline abstract_t">Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 2007; 5:901.</a></li><li><a class="nounderline abstract_t">Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431.</a></li><li><a class="nounderline abstract_t">Kasuda S, Kubo A, Sakurai Y, et al. Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A. J Thromb Haemost 2008; 6:1352.</a></li><li><a class="nounderline abstract_t">Kren BT, Unger GM, Sjeklocha L, et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009; 119:2086.</a></li><li><a class="nounderline abstract_t">Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program 2019; 2019:1.</a></li><li><a class="nounderline abstract_t">Aljamali MN, Margaritis P, Schlachterman A, et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 2008; 118:1825.</a></li><li><a class="nounderline abstract_t">Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009; 113:3682.</a></li><li class="breakAll">https://www.ashclinicalnews.org/spotlight/feature-articles/gene-therapy-hemophilia-progress-setbacks/ (Accessed on November 16, 2021).</li><li><a class="nounderline abstract_t">George LA. Hemophilia gene therapy comes of age. Hematology Am Soc Hematol Educ Program 2017; 2017:587.</a></li><li><a class="nounderline abstract_t">Schäffer AA, Dominguez DA, Chapman LM, et al. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis. BMC Genomics 2021; 22:814.</a></li><li><a class="nounderline abstract_t">Dalwadi DA, Calabria A, Tiyaboonchai A, et al. AAV integration in human hepatocytes. Mol Ther 2021; 29:2898.</a></li><li class="breakAll">https://www.science.org/content/article/experimental-gene-therapy-hemophilia-probably-did-not-cause-patient-s-liver-tumor (Accessed on November 17, 2021).</li><li class="breakAll">https://hemophilianewstoday.com/2021/03/31/hemophilia-b-gene-therapy-amt-061-unlikely-to-have-caused-liver-tumor-cancer-case/ (Accessed on November 17, 2021).</li><li class="breakAll">http://uniqure.com/ISTH_HCC%20case%20study_June%2023_Final.pdf (Accessed on November 17, 2021).</li><li class="breakAll">https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-277-masac-recommendations-on-hemophilia-treatment-center-preparedness-for-delivering-gene-therapy-for-hemophilia (Accessed on October 23, 2023).</li><li><a class="nounderline abstract_t">Powell JS, Ragni MV, White GC 2nd, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102:2038.</a></li><li><a class="nounderline abstract_t">George LA, Monahan PE, Eyster ME, et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med 2021; 385:1961.</a></li><li><a class="nounderline abstract_t">Favaro P, Finn JD, Siner JI, et al. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model. Hum Gene Ther 2011; 22:843.</a></li><li><a class="nounderline abstract_t">High KA. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia. Trans Am Clin Climatol Assoc 2003; 114:337.</a></li><li><a class="nounderline abstract_t">Majowicz A, Nijmeijer B, Lampen MH, et al. Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs. Mol Ther Methods Clin Dev 2019; 14:27.</a></li><li><a class="nounderline abstract_t">13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5-7 February 2020, The Hague, The Netherlands. Haemophilia 2020; 26 Suppl 2:12.</a></li><li class="breakAll">ROCTAVIAN, INN-valoctocogene roxaparvovec. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf (Accessed on November 02, 2022).</li><li class="breakAll">FDA news release https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia (Accessed on June 30, 2023).</li><li><a class="nounderline abstract_t">Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med 2017; 377:2519.</a></li><li><a class="nounderline abstract_t">Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med 2022; 386:1013.</a></li><li><a class="nounderline abstract_t">Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med 2023; 388:694.</a></li><li class="breakAll">https://hemophilianewstoday.com/2020/12/11/high-dose-gene-therapy-sb-525-fviii-levels-prevents-bleeds-alta-trial-data/ (Accessed on November 17, 2021).</li><li><a class="nounderline abstract_t">Roth DA, Tawa NE Jr, O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344:1735.</a></li><li class="breakAll">FDA Approves First Gene Therapy to Treat Adults with Hemophilia B. US Food and Drug Administration. Available at: https://content.govdelivery.com/accounts/USFDA/bulletins/3396c72 (Accessed on November 22, 2022).</li><li><a class="nounderline abstract_t">Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3:3241.</a></li><li><a class="nounderline abstract_t">Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 2018; 131:1022.</a></li><li><a class="nounderline abstract_t">Pipe SW, Leebeek FWG, Recht M, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med 2023; 388:706.</a></li><li><a class="nounderline abstract_t">von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv 2023; 7:5671.</a></li><li><a class="nounderline abstract_t">Chowdary P, Shapiro S, Makris M, et al. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. N Engl J Med 2022; 387:237.</a></li><li><a class="nounderline abstract_t">George LA, Sullivan SK, Giermasz A, et al. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 2017; 377:2215.</a></li><li><a class="nounderline abstract_t">Porteus M. Closing In on Treatment for Hemophilia B. N Engl J Med 2017; 377:2274.</a></li><li><a class="nounderline abstract_t">Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365:2357.</a></li><li><a class="nounderline abstract_t">Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371:1994.</a></li><li><a class="nounderline abstract_t">Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008; 118:935.</a></li><li class="breakAll">https://www.fiercebiotech.com/biotech/fda-puts-sigilon-s-hemophilia-cell-therapy-trial-hold-thanks-to-safety-concerns (Accessed on March 25, 2022).</li><li class="breakAll">https://www.biospace.com/article/sigilon-may-have-discovered-what-caused-the-clinical-hold-of-its-hemophilia-cell-therapy/ (Accessed on March 25, 2022).</li><li class="breakAll">https://www.hemophilia.org/news/sigilon-announces-a-priority-shift-in-light-of-clinical-trial-setbacks (Accessed on March 25, 2022).</li><li><a class="nounderline abstract_t">Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood 2021; 138:1258.</a></li><li><a class="nounderline abstract_t">Mahlangu JN. Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management. Front Med (Lausanne) 2021; 8:670526.</a></li><li><a class="nounderline abstract_t">Parunov LA, Soshitova NP, Fadeeva OA, et al. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A. Thromb Res 2014; 133:112.</a></li><li class="breakAll">Alhemo™ concizumab injection. Novo Nordisk Canada Inc. March 10, 2023. Available at: https://pdf.hres.ca/dpd_pm/00069890.PDF (Accessed on March 28, 2023).</li><li><a class="nounderline abstract_t">Matsushita T, Shapiro A, Abraham A, et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med 2023; 389:783.</a></li><li><a class="nounderline abstract_t">Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood 2019; 134:1973.</a></li><li><a class="nounderline abstract_t">Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13:743.</a></li><li><a class="nounderline abstract_t">Agersø H, Overgaard RV, Petersen MB, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci 2014; 56:65.</a></li><li><a class="nounderline abstract_t">Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost 2018; 16:2184.</a></li><li><a class="nounderline abstract_t">Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet 2023; 401:1427.</a></li><li><a class="nounderline abstract_t">Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med 2017; 377:819.</a></li><li class="breakAll">http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1039464 (Accessed on September 07, 2017).</li><li class="breakAll">https://hemophilianewstoday.com/2021/03/01/fitusiran-dosing-phase-3-trials-reduced-to-lower-risk-of-blood-clots (Accessed on November 18, 2021).</li><li class="breakAll">https://www.hemophilia.org/news/sanofi-revises-fitusiran-dosing-regimen-to-mitigate-risk-of-vascular-thrombosis (Accessed on November 18, 2021).</li><li><a class="nounderline abstract_t">Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost 2021; 19:1436.</a></li><li><a class="nounderline abstract_t">Jiang M, Yang F, Jiang Y, et al. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models. Blood 2023; 142:1071.</a></li></ol></div><div id="topicVersionRevision">Topic 134290 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35521726" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Haemophilia gene therapy-Update on new country initiatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32490590" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Delivering on the promise of gene therapy for haemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31664646" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31248872" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gene editing in hemophilia: a "CRISPR" choice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559260" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Update on clinical gene therapy for hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33183859" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Discussing investigational AAV gene therapy with hemophilia patients: A guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17459005" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441245" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Development of gene therapy for blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485084" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509468" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31808868" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gene therapy for hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398505" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109232" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Successful treatment of canine hemophilia by continuous expression of canine FVIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109232" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Successful treatment of canine hemophilia by continuous expression of canine FVIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222308" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hemophilia gene therapy comes of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34763675" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34461297" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : AAV integration in human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34461297" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : AAV integration in human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34461297" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : AAV integration in human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34461297" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : AAV integration in human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34461297" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : AAV integration in human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763932" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34788507" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21126217" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12813929" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31276009" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31991514" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5-7 February 2020, The Hague, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31991514" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5-7 February 2020, The Hague, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31991514" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5-7 February 2020, The Hague, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29224506" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35294811" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36812433" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36812433" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11396439" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11396439" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31698454" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246900" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36812434" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36490302" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35857660" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211678" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211662" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Closing In on Treatment for Hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22149959" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25409372" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term safety and efficacy of factor IX gene therapy in hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274668" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274668" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274668" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274668" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077951" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34026796" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24263002" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24263002" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37646676" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444162" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25641556" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24568891" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137664" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37003287" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691885" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691885" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691885" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691885" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33587824" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37294924" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
